Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Photodynamic prevention for GvHD (graft-versus-host disease) shows promise :

This article was originally published in Clinica

Executive Summary

Theratechnologies subsidiary Celmed BioSciences says that it is gearing up to start human trials of its Theralux photodynamic process for preventing and treating graft-versus-host disease (GvHD) later this year. The announcement follows positive results from a new study - the first to be conducted in vitro on immunoreactive T cells, notes the Montreal, Canada firm. The study showed that the cells responsible for GvHD were selectively eliminated by the Theralux process, without destroying dormant T cells carrying immune and anti-leukaemic functions. The findings appear in Blood (July 15).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel